There is no way Arcus Biosciences Inc. (RCUS) can keep these numbers up

Arcus Biosciences Inc. (NYSE: RCUS) stock fell -3.05% on Thursday to $17.50 against a previous-day closing price of $18.05. With 1.01 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.98 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $18.00 whereas the lowest price it dropped to was $16.91. The 52-week range on RCUS shows that it touched its highest point at $36.13 and its lowest point at $15.70 during that stretch. It currently has a 1-year price target of $43.00. Beta for the stock currently stands at 0.87.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RCUS was down-trending over the past week, with a drop of -0.62%, but this was down by -2.72% over a month. Three-month performance dropped to -4.42% while six-month performance fell -35.59%. The stock lost -2.51% in the past year, while it has lost -15.38% so far this year. A look at the trailing 12-month EPS for RCUS yields -3.85 with Next year EPS estimates of -3.99. For the next quarter, that number is -1.15. This implies an EPS growth rate of -619.20% for this year and 13.60% for next year.

Float and Shares Shorts:

At present, 73.00 million RCUS shares are outstanding with a float of 51.46 million shares on hand for trading. On Apr 27, 2023, short shares totaled 7.81 million, which was 10.69% higher than short shares on Mar 30, 2023. In addition to Dr. Terry J. Rosen Ph.D. as the firm’s Co-Founder, Chairman & CEO, Dr. Juan Carlos Jaen Ph.D. serves as its Co-Founder, Pres & Director.

Institutional Ownership:

Through their ownership of 75.68% of RCUS’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 47.23% of RCUS, in contrast to 43.24% held by mutual funds. Shares owned by individuals account for 27.65%. As the largest shareholder in RCUS with 11.89% of the stake, BlackRock Fund Advisors holds 8,681,419 shares worth 8,681,419. A second-largest stockholder of RCUS, SSgA Funds Management, Inc., holds 5,496,253 shares, controlling over 7.53% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in RCUS, holding 4,340,909 shares or 5.95% stake. With a 5.18% stake in RCUS, the iShares Core S&P Small Cap ETF is the largest stakeholder. A total of 3,785,223 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 4.85% of RCUS stock, is the second-largest Mutual Fund holder. It holds 3,540,513 shares valued at 63.2 million. Fidelity Select Port. – Biotechno holds 4.37% of the stake in RCUS, owning 3,193,396 shares worth 57.0 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, RCUS reported revenue of $26.76M and operating income of -$68.98M. The EBITDA in the recently reported quarter was -$64.62M and diluted EPS was -$0.93.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RCUS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RCUS analysts setting a high price target of $70.00 and a low target of $22.00, the average target price over the next 12 months is $43.00. Based on these targets, RCUS could surge 300.0% to reach the target high and rise by 25.71% to reach the target low. Reaching the average price target will result in a growth of 145.71% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded RCUS stock several times over the past three months with 0 Buys and 1 Sells. In these transactions, 0 shares were bought while 8,729 shares were sold. The number of buy transactions has increased to 14 while that of sell transactions has risen to 26 over the past year. The total number of shares bought during that period was 370,500 while 91,584 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *